BioNTech appoints Sobi CEO Guido Oelkers as new chief, founders to launch separate mRNA biotech
BioNTech announced that Guido Oelkers, current chief executive of Swedish Orphan Biovitrum (Sobi), will assume the role of CEO in early 2027.
The move follows the earlier decision of co‑founders Ugur Sahin and Özlem Türeci to depart the company and start a new mRNA‑focused biotechnology venture.
Oelkers brings a track record of scaling innovation‑driven organizations in hematology, immunology and specialty care, having overseen Sobi’s products such as Tryngolza and Zynlonta.
The board said his capital‑efficient approach and deep market knowledge position BioNTech for continued growth, while a search for a new chief medical officer remains ongoing.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that